Inventiva SA
PAR:IVA

Watchlist Manager
Inventiva SA Logo
Inventiva SA
PAR:IVA
Watchlist
Price: 2.76 EUR 1.66% Market Closed
Market Cap: 264m EUR

Inventiva SA
Investor Relations

Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. The company is headquartered in Daix, Occitanie and currently employs 100 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.

Show more
Loading

Earnings Calls

2025 Q3
Mar 4, 2025
Show Transcript
Previous
Next
Ashtead Group Reports Strong Revenue Growth Amid Market Challenges
2025 Q3
Mar 4, 2025

Ashtead Group's Q3 results highlighted a 5% increase in group rental revenue and strong margins, with total EBITDA growth of 3% to $3.9 billion. U.S. rental revenue rose 4% to a record $6.6 billion, despite challenges in local construction, buoyed by strong mega project activity contributing nearly $100 million in revenue. The company maintained guidance of 3-5% revenue growth for the year, with anticipated U.S. growth of 2-4% and Canadian growth between 9-13%. A share buyback program was initiated, aiming for up to $1.5 billion over 18 months, reflecting confidence in cash flow management.

Show Full Analysis

Management

Mr. Frederic Cren
Co-Founder, CEO & Chairman
No Bio Available
Dr. Pierre Broqua Ph.D.
Co-Founder, Chief Scientific Officer, Deputy CEO & Director
No Bio Available
Mr. Jean Volatier
Deputy GM & CFO
No Bio Available
Ms. Alice Roudot-Ketelers Pharm.D.
Chief Operating Officer
No Bio Available
Mr. Eric Duranson L.L.M.
General Counsel
No Bio Available
Ms. Nathalie Harroy
Head of Human Resources
No Bio Available
Dr. Kristina Meyer Ph.D.
Executive VP and Business Development & Alliance Management
No Bio Available
Dr. Michael Cooreman
Chief Medical Officer
No Bio Available
Ms. Pascaline Clerc Ph.D.
Executive Vice President of Strategy & Corporate Affairs
No Bio Available

Contacts

Address
OCCITANIE
Daix
50 rue de Dijon, Daix
Contacts
+33380447500.0
inventivapharma.com